TABLE OF CONTENTS
Volume 15, Issue 11 (June 2008)
Special Issue: AAV Vectors for Clinical Gene Therapy
Guest Editor: Robert M Kotin, National Institutes of Health,
Bethesda, MD, USA
Editorial
Introduction to AAV Vector special issue
M Nirenberg
Gene Ther 15: 807; doi:10.1038/gt.2008.62
Review Articles
Immunity to adeno-associated virus vectors in animals and humans: a continued challenge
A K Zaiss and D A Muruve
Gene Ther 15: 808-816; advance online publication, April 3, 2008; doi:10.1038/gt.2008.54
Adeno-associated virus integration: virus versus vector
R H Smith
Gene Ther 15: 817-822; advance online publication, April 10, 2008; doi:10.1038/gt.2008.55
Toward exascale production of recombinant adeno-associated virus for gene transfer applications
S Cecchini, A Negrete and R M Kotin
Gene Ther 15: 823-830; advance online publication, April 10, 2008; doi:10.1038/gt.2008.61
Potential of AAV vectors in the treatment of metabolic disease
I E Alexander, S C Cunningham, G J Logan and J Christodoulou
Gene Ther 15: 831-839; advance online publication, April 10, 2008; doi:10.1038/gt.2008.64
Manufacturing and characterizing AAV-based vectors for use in clinical studies
J F Wright
Gene Ther 15: 840-848; advance online publication, April 17, 2008; doi:10.1038/gt.2008.65
AAV-mediated gene therapy for retinal disorders: from mouse to man
P K Buch, J W Bainbridge and R R Ali
Gene Ther 15: 849-857; advance online publication, April 17, 2008; doi:10.1038/gt.2008.66
Clinical gene therapy using recombinant adeno-associated virus vectors
C Mueller and T R Flotte
Gene Ther 15: 858-863; advance online publication, April 17, 2008; doi:10.1038/gt.2008.68
AAV vectors for RNA-based modulation of gene expression
O Danos
Gene Ther 15: 864-869; advance online publication, April 17, 2008; doi:10.1038/gt.2008.69